Stockscreener 앱 받기
13.33
4.31%
-0.60
전일 마감가:
$13.93
열려 있는:
$13.86
하루 거래량:
729.27K
Relative Volume:
0.50
시가총액:
$1.89B
수익:
-
순이익/손실:
$-45.61M
주가수익비율:
-41.21
EPS:
-0.3235
순현금흐름:
$-45.40M
1주 성능:
-5.73%
1개월 성능:
-9.07%
6개월 성능:
-1.04%
1년 성능:
+97.77%
1일 변동 폭
$13.31
$13.93
1주일 범위
$13.25
$14.18
52주 변동 폭
$5.41
$16.12
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
13.33 | 1.98B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Trevi Therapeutics Shareholders Approve Stock and Governance Changes - The Globe and Mail
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Trevi Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
TRVI: All proposals passed, including share increase and director election, with no shareholder questions - TradingView
Pivotal bioVenture Partners Increases Trevi Therapeutics Holdings by 296,944 Shares in Q1 2026News and Statistics - IndexBox
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. - Yahoo Finance
Trevi Therapeutics stock hits 52-week low at 13.68 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week low at 13.68 USD - Investing.com
Trevi Therapeutics (TRVI) Shows Potential as Shares Climb Over 2%OBV Divergence - thelegaladvocate.com
Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation - MSN
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - MSN
TRVI Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Shares Edge HigherRevenue Inflection Point - thelegaladvocate.com
Trevi Therapeutics Q1 2026 Earnings: Narrowing Losses but Trial Failures Weigh on SentimentPost-Announcement Reaction - thelegaladvocate.com
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Quantisnow
TRVI Reiterated by Needham -- Price Target Maintained at $23 - GuruFocus
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal u - AD HOC NEWS
Trevi Therapeutics (TRVI) Q1 2026 Earnings: Miss Sparks ConcernProfit Margin Analysis - thelegaladvocate.com
Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GuruFocus
Trevi Therapeutics, Inc. (TRVI) Analyst/Investor DaySlideshow (NASDAQ:TRVI) 2026-05-15 - Seeking Alpha
Trevi Therapeutics, Inc.Common Stock (Nasdaq:TRVI) Stock Quote - FinancialContent
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
TradingKey - TradingKey
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
TRVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - sharewise.com
Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Equities Analysts Offer Predictions for TRVI Q2 Earnings - MarketBeat
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech With 59.82% Potential Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21 - Moomoo
NEA stake in Trevi now 10.5% on share increase (TRVI) - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Research Analysts Set Expectations for TRVI FY2030 Earnings - MarketBeat
Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 - Yahoo Finance
FMR LLC shows 6.3% stake in Trevi Therapeutics (NASDAQ: TRVI) - Stock Titan
B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating - marketscreener.com
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.13%
3.22%
자본화:
|
볼륨(24시간):